Medical University of Innsbruck, Department for Internal Medicine I Trials

Medical University of Innsbruck, Department for Internal Medicine I	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Eisterer, Wolfgang

PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Active, not recruiting

556

Europe, Canada, US, RoW

NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel

NovoCure Ltd.

Pancreas Adenocarcinoma

09/24

10/24

INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting

450

Europe, Japan, US, RoW

Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf

Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health

Gastro-Oesophageal Cancer

06/25

06/26

ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Recruiting

2/3

600

Europe, US, RoW

SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo

Panbela Therapeutics, Inc.

Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV

08/26

01/27

Wolf, Dominik

LUSPLUS, NCT05181592: Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.

Recruiting

Europe

Luspatercept, Reblozyl

GWT-TUD GmbH, Celgene

Myelodysplastic Syndromes

12/24

06/25

CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting

897

Europe, RoW

Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro

German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG)

Chronic Lymphoid Leukemia

03/27

DASTOP2, NCT03573596: Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment

Recruiting

134

Europe

Dasatinib

Amsterdam UMC, location VUmc, Uppsala University Hospital, Skane University Hospital, Helsinki University Central Hospital, Odense University Hospital, Henri Mondor University Hospital, St. Olavs Hospital, Helse Stavanger HF, Aarhus University Hospital, University Hospital, Bonn

CML, Relapsed

02/23

02/24

CLL-Frail, NCT04883749: Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL

Active, not recruiting

Europe

Acalabrutinib, Calquence, ACP-196

German CLL Study Group

Chronic Lymphoid Leukemia

07/23

12/24

DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Recruiting

168

Europe, RoW

MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab

Miltenyi Biomedicine GmbH, ICON plc

Diffuse Large B-cell Lymphoma

12/24

07/27

PALINDROM, NCT06172894: PBMC-based Leukocyte Immunotherapy

Recruiting

Europe

APN401

invIOs GmbH

Advanced Solid Tumor

03/24

NCT06250465: AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry

Recruiting

N/A

500

Europe

Arbeitsgemeinschaft medikamentoese Tumortherapie

Chronic Lymphocytic Leukemia

12/27

InflamGen, NCT04313231: Sterile Inflammation and Molecular Aberrations in MDS

Recruiting

N/A

130

Europe

Next Generation Sequencing, Tumorimmunological examinations - multiplex assays/quantitative polymerase chain reaction, flow cytometry, Metagenomics of stool samples, Clinical/demographic data, Elicitation of the HRQoL

Medical University Innsbruck, University Hospital, Bonn, Universitätsklinikum Leipzig

Myelodysplastic Syndromes

01/23

PRO-RED, NCT05582902: Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients

Recruiting

N/A

Europe

University of Leipzig, Deutsche Krebshilfe e.V., Bonn (Germany)

MDS, MDS/MPN

03/25

Sprinzl, Georg

NCT05565339: PMEI Post-Market Clinical Follow-Up

Completed

N/A

497

Europe

PMEIs

MED-EL Elektromedizinische Geräte GesmbH

Pre-existing Condition

11/23

NCT04427033: The BCI 602 BONEBRIDGE Post-Market Clinical Follow-up Study

Completed

N/A

Europe

Bone Conduction Implant

MED-EL Elektromedizinische Geräte GesmbH

Hearing Loss, Hearing Loss, Conductive, Hearing Loss, Mixed, Hearing Loss, Unilateral, Hearing Loss, Bilateral, Hearing Loss, Sensorineural

01/24

LÃ¶ffler-Ragg, Judith

NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting

1000

Europe, Canada, US, RoW

Ralinepag, APD811, Placebo

United Therapeutics

PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease

12/24

Colipris, NCT04095351: Connective Tissue Diseases and Lung Manifestations

Recruiting

N/A

120

Europe

Pulmonary function test, Imaging, Blood sampling

Medical University Innsbruck, Boehringer Ingelheim

Connective Tissue Diseases, Interstitial Lung Disease, Systemic Sclerosis

03/21

10/34

NCT04661462: Health After Covid-19 in Tyrol

Recruiting

N/A

1000

Europe

online survey

Medical University Innsbruck, Claudiana Landesfachhochschule

COVID-19

09/21

12/21

PRECISE, NCT05545332: Prospective Multidisciplinary Post-COVID-19 Registry Tyrol

Recruiting

N/A

600

Europe

Medical University Innsbruck

Post COVID-19 Condition

12/23

12/25

Pall, Georg

INNWOP1, NCT04875585: Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC

Recruiting

Europe

neoadjuvant therapy with Pembrolizumab/Lenvatinib, Surgery, Adjuvant Treatment Phase

Medical University Innsbruck, Merck Sharp & Dohme LLC

Non Small Cell Lung Cancer

12/23

12/27

AGMT_LungCA-Reg, NCT04654364: Lung Cancer Registry

Recruiting

N/A

500

Europe

Arbeitsgemeinschaft medikamentoese Tumortherapie

Lung Cancer, NSCLC Stage IV, NSCLC, Stage III, SCLC, Extensive Stage, SCLC, Limited Stage

08/30

Gassner, Eva-Maria

No trials found

Schartinger, Volker Hans

No trials found

Strasser, Ulrich

No trials found

DudÃ s, JÃ²zsef

No trials found

Gamerith, Gabriele

No trials found



	Diseases Companies Products Productz Mechanisms of Action Sites